Richard Lehman’s journal review—6 May 2014

NEJM  1 May 2014  Vol 370 1702  Britons, mourn. Our biggest drug company, GlaxoSmithKline, had a potential blockbuster on its hands. Darapladib would stabilise unstable plaque, everybody would want to take it, and GSK would make billions. But, although darapladib is a selective oral inhibitor of lipoprotein associated phospholipase A2, which is an enzyme associated […]

Read More…

Richard Lehman’s journal review—31 March 2014

NEJM  27 Mar 2014  Vol 370 1189   I sing the body mitotic: we are a mass of cells dividing, mutating, cannibalizing, spreading. The wonder is not that we ever die of cancer, but that we often don’t. Cells which become aggressive are extraordinarily versatile at remaining aggressive, as shown by the relatively rare ALK-Rearranged Non–Small-Cell […]

Read More…

Richard Lehman’s journal review—24 March 2013

NEJM   20 Mar 2014  Vol 370 1091    Please follow these instructions carefully: 1. Remove half of the skull, taking care to ensure you have chosen the appropriate side. 2. Repair the dura over the swollen brain and replace the scalp. 3. Wrap the removed skull and place in a refrigerator, choosing a shelf free of […]

Read More…

Richard Lehman’s journal review—17 March 2014

NEJM  13 Mar 2014  Vol 370 1029 Doctors, by and large, make bad scientists. We train our minds for years in some of the hardest intellectual disciplines, and then make do with the sloppiest excuse for thought when it comes to believing what we wish to. All of us learned, at some time between the […]

Read More…

Richard Lehman’s journal review—10 March 2014

NEJM  6 Mar 2014  Vol 370 901    The cat and mouse game of man versus human immunodeficiency virus has just taken a new turn. HIV kills off CD4 T cells by binding to the CCR5 receptor. Now if you could manufacture CD4 T cells without a functioning CCR5 receptor, the virus would not be able […]

Read More…